E/C/F/TAF
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for E/C/F/TAF, covering 2016-01-08 to 2024-02-09. Get the full timeline:
Most recent: Clinical Trial Update: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) [Phase 3]